Orlistat increases serum paraoxonase activity in obese patients

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 4, 2007, Pages 268-273

  Audikovszky, Mária ^b   Pados, Gyula ^b   Seres, Ildikó ^a   Harangi, Mariann ^a   Fülöp, Péter ^a   Katona, Evelin ^a   Illyés, László ^c   Winkler, Gábor ^d   Katona, Éva M ^a   Paragh, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Szent Imre Hospital   (Hungary)

^c Szent Ferenc Hospital   (Hungary)

^d ST JOHN'S HOSPITAL   (Hungary)

Author keywords

Lipids; Obesity; Orlistat; Paraoxonase

Indexed keywords

ANTIOBESITY AGENT; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; TETRAHYDROLIPSTATIN;

ADULT; AGED; ARTICLE; BLOOD; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIPID PEROXIDATION; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBESITY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTI-OBESITY AGENTS; ARYLDIALKYLPHOSPHATASE; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; LACTONES; LIPID PEROXIDATION; LONGITUDINAL STUDIES; MALE; MALONDIALDEHYDE; MIDDLE AGED; OBESITY;

EID: 34047262851     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2006.03.004     Document Type: Article

References (33)

1. Keaney Jr. J.F., Larson M.G., Vasan R.S., Wilson P.W., Lipinska I., Corey D., et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the framingham study. Arterioscler Thromb Vasc Biol 23 (2003) 434-439
2. Morrow J.D. Is oxidant stress a connection between obesity and atherosclerosis?. Arterioscler Thromb Vasc 23 (2003) 368-373
3. Yesilbursa D., Serdar Z., Serdar A., Sarac M., Coskun S., and Jale C. Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels. Int J Obes Relat Metab Disord 29 (2005) 142-145
4. Mackness M.I., Abbott C., Arrol S., and Durrington P.N. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 294 (1993) 829-834
5. Mackness M.I., and Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115 (1995) 243-253
6. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139 (1998) 341-349
7. Mackness M.I., Peuchant E., Dumon M.F., Walker C.H., and Clerc M. Absence of "A"-esterase activity in the serum of a patient with Tangier disease. Clin Biochem 22 (1989) 475-478
8. Paragh G., Seres I., Balogh Z., Varga Z., Karpati I., Matyus J., et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80 (1998) 166-170
9. Ferretti G., Bacchetti T., Moroni C., Savino S., Liuzzi A., Balzola F., et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 90 (2005) 1728-1733
10. Dattilo A.M., and Kris-Etherton P.M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56 (1992) 320-328
11. Goldstein D.I. Beneficial health effects of modest weight loss. Int J Obes 16 (1992) 397-415
12. Williamson D.F., Pamuk E., Thus M., Flanders D., Byers T., and Heath C. Prospective study of intentional weight loss and mortality in never-smoking US white women age 40-64 years. Am J Epidemol 141 (1995) 1128-1141
13. Golay A., and Bobbioni E. The role of dietary fat in obesity. Int J Obes 21 (1997) 2S-11S
14. Bray G.A., and Popkin B.M. Dietary fat intake does affect obesity. Am J Clin Nutr 68 (1998) 1157-1173
15. Muls E., Kolanowski J., Scheen A., and VanGall L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled multicentre study. Int J Obesity 25 (2001) 1703-1721
16. Rossner S.T., Sjöström L., Noack R., Meinders E., and Noseda G. Weight loss, weight maintenance and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 8 (2000) 49-61
17. Petrogiannopoulos C., Kalogeropoulos S., Latsios G.S., Hartzoulakis G., Kalogeropoulos G., and Zaharof A. Orlistat use in overweight women with mild hypercholesterolemia. Int J Clin Pharmacol Res 22 (2002) 85-88
18. Audikovszky M., Pados G., Seres I., Harangi M., Fulop P., Katona E., et al. Changes in lipid profile and paraoxonase activity in obese patients as a result of orlistat treatment. Orv Hetil 142 (2001) 2779-2783
19. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
20. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., and Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15 (1995) 1812-1818
21. Castro Cabezas M., Halkes C.J., and Erhkelens D.W. Obesity and free fatty acids: double trouble. Nutr Metab Cardiovasc Dis 11 (2001) 134-142
22. Scheen A.J. Results of obesity treatment. Ann Endocrinol 63 (2002) 163-170
23. Sjöström L., Rissanen A., Andersen T., Boldrin M., Golay A., Koppeschaar H.P., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352 (1998) 167-172
24. Davidson M.H., Hauptman J., DiGirolamo M., Foreyt J.P., and Halsted C.H. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 281 (1999) 235-242
25. Finer N., James W.P.T., Kopelman P.G., Lean M.E.J., and Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicenter study of orlistat, a gastrointestinal lipase inhibitor. Int J Obesity 24 (2000) 306-313
26. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 248 (2000) 245-254
27. Fujioka K. Management of obesity as a chronic disease. Obes Res 10 (2002) 116S-123S
28. Reaven G., Segal K., Hauptman J., Bodrin M., and Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 87 (2001) 827-831
29. Derosa G., Mugellini A., Ciccarelli L., and Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 25 (2003) 1107-1122
30. Erdmann J., Lippl F., Klose G., and Schusdziarra V. Cholesterol lowering effect of dietary weight loss and orlistat treatment - efficacy and limitations. Aliment Pharmacol Ther 19 (2004) 1173-1179
31. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., and Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15 (1995) 1812-1818
32. Kontush A., Chantepie S., and Chapman M.J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23 (2003) 1881-1888
33. Oczelik O., Ozkan Y., Karatas F., and Kelestimur H. Exercise training as an adjunct to orlistat therapy reduces oxidative stress in obese subjects. Tohoku J Exp Med 206 (2005) 313-318